Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maxime Dougados

Showing results (511-520 of 600) with videos related to

Pageof 60
Sort By:
Arthritis and Rheumatism|November 1, 2006
Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis studyClifton O Bingham, J Chris Buckland-Wright, Patrick Garnero, et al.
The Journal of Rheumatology|August 17, 2013
Five-year favorable outcome of patients with early rheumatoid arthritis in the 2000s: data from the ESPOIR cohortBernard Combe, Nathalie Rincheval, Joelle Benessiano, et al.
Annals of the Rheumatic Diseases|May 8, 2012
After treat-to-target: can a targeted ultrasound initiative improve RA outcomes?Richard J Wakefield, Maria Antonietta D'Agostino, Esperanza Naredo, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 4, 2014
Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trialMaxime Dougados, Désirée van der Heijde, Joachim Sieper, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|September 24, 2015
Assessment of Global Disease Activity in Rheumatoid Arthritis by Patients and Physicians: Differences Across Countries in the METEOR DatabaseEmilia Gvozdenović, Ron Wolterbeek, Cornelia F Allaart, et al.
Seminars in Arthritis and Rheumatism|November 6, 2017
Systematic switch from innovator infliximab to biosimilar infliximab in inflammatory chronic diseases in daily clinical practice: The experience of Cochin University Hospital, Paris, FranceJérôme Avouac, Anna Moltó, Vered Abitbol, et al.
Annals of the Rheumatic Diseases|September 24, 2025
Use of statins and its association with major adverse cardiovascular events with tofacitinib vs TNF inhibitors in patients with rheumatoid arthritis with and without atherosclerotic cardiovascular diseaseJon T Giles, Christina Charles-Schoeman, Maya H Buch, et al.
Annals of the Rheumatic Diseases|December 3, 2020
Immune response profiling of patients with spondyloarthritis reveals signalling networks mediating TNF-blocker function in vivoSilvia Menegatti, Vincent Guillemot, Eleonora Latis, et al.
Clinical and Experimental Rheumatology|September 3, 2016
The unmet need in rheumatology: reports from the Targeted Therapies meeting 2016Kevin L Winthrop, Vibeke Strand, Désiréé M van der Heijde, et al.
Clinical Immunology (Orlando, Fla.)|August 17, 2017
The unmet need in rheumatology: Reports from the targeted therapies meeting 2017Kevin L Winthrop, Vibeke Strand, Désirée van der Heijde, et al.
Pageof 60

Showing results (511-520 of 600) with videos related to

Sort By:
Pageof 60
Arthritis and Rheumatism|November 1, 2006
Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis studyClifton O Bingham, J Chris Buckland-Wright, Patrick Garnero, et al.
The Journal of Rheumatology|August 17, 2013
Five-year favorable outcome of patients with early rheumatoid arthritis in the 2000s: data from the ESPOIR cohortBernard Combe, Nathalie Rincheval, Joelle Benessiano, et al.
Annals of the Rheumatic Diseases|May 8, 2012
After treat-to-target: can a targeted ultrasound initiative improve RA outcomes?Richard J Wakefield, Maria Antonietta D'Agostino, Esperanza Naredo, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 4, 2014
Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trialMaxime Dougados, Désirée van der Heijde, Joachim Sieper, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|September 24, 2015
Assessment of Global Disease Activity in Rheumatoid Arthritis by Patients and Physicians: Differences Across Countries in the METEOR DatabaseEmilia Gvozdenović, Ron Wolterbeek, Cornelia F Allaart, et al.
Seminars in Arthritis and Rheumatism|November 6, 2017
Systematic switch from innovator infliximab to biosimilar infliximab in inflammatory chronic diseases in daily clinical practice: The experience of Cochin University Hospital, Paris, FranceJérôme Avouac, Anna Moltó, Vered Abitbol, et al.
Annals of the Rheumatic Diseases|September 24, 2025
Use of statins and its association with major adverse cardiovascular events with tofacitinib vs TNF inhibitors in patients with rheumatoid arthritis with and without atherosclerotic cardiovascular diseaseJon T Giles, Christina Charles-Schoeman, Maya H Buch, et al.
Annals of the Rheumatic Diseases|December 3, 2020
Immune response profiling of patients with spondyloarthritis reveals signalling networks mediating TNF-blocker function in vivoSilvia Menegatti, Vincent Guillemot, Eleonora Latis, et al.
Clinical and Experimental Rheumatology|September 3, 2016
The unmet need in rheumatology: reports from the Targeted Therapies meeting 2016Kevin L Winthrop, Vibeke Strand, Désiréé M van der Heijde, et al.
Clinical Immunology (Orlando, Fla.)|August 17, 2017
The unmet need in rheumatology: Reports from the targeted therapies meeting 2017Kevin L Winthrop, Vibeke Strand, Désirée van der Heijde, et al.
Pageof 60